Yoshihiro Yoshino1, Shouhei Takeuchi1, Takahiko Katoh2, Yoshiki Kuroda3. 1. Department of Public Health, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan. 2. Department of Public Health, Faculty of Life Science, University of Kumamoto, 1-1-1 Honjyoh, Chuou-ku, Kumamoto, 860-8556, Japan. 3. Department of Public Health, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan. ykuroda@med.miyazaki-u.ac.jp.
Abstract
OBJECTIVES: DNA repair genes play an important role in protection against environmental and endogenous DNA damage, and constitute the first line of defense against cancer. Xeroderma pigmentosum complementation group C (XPC) is involved in the damage recognition step during nucleotide excision repair. The relationship between XPC intron11 C/A polymorphism and cancer risk has not been widely studied. Hence, this study evaluated the relationship between the XPC intron11 C/A polymorphism and prostate cancer risk. MATERIALS AND METHODS: This hospital-based cohort consisted of 152 patients with prostate cancer and 142 male controls. The XPC intron11 C/A genotype was determined using the PCR-RFLP method. Medical, occupational, and cigarette-smoking history was obtained from each participant using questionnaires. RESULTS: Logistic regression analysis revealed that compared to controls, the frequencies of the A/A and C/A genotypes were significantly higher than those of the C/C genotype in cancer patients (OR = 2.03, 95% confidence interval (CI) 1.03-3.98 and OR = 1.91, 95% CI 1.13-3.24, respectively). We also found that the frequency of the A/A genotype was significantly higher in cancer cases than in controls among non-smokers (OR = 7.7, 95% CI 1.38-42.88, compared to the C/C genotype). CONCLUSION: We found that the XPC intron11 C/A polymorphism was associated with an increased risk of prostate cancer. Among non-smokers, the A/A genotype was significantly more prevalent in prostate cancer patients than in controls.
OBJECTIVES: DNA repair genes play an important role in protection against environmental and endogenous DNA damage, and constitute the first line of defense against cancer. Xeroderma pigmentosum complementation group C (XPC) is involved in the damage recognition step during nucleotide excision repair. The relationship between XPC intron11 C/A polymorphism and cancer risk has not been widely studied. Hence, this study evaluated the relationship between the XPC intron11 C/A polymorphism and prostate cancer risk. MATERIALS AND METHODS: This hospital-based cohort consisted of 152 patients with prostate cancer and 142 male controls. The XPC intron11 C/A genotype was determined using the PCR-RFLP method. Medical, occupational, and cigarette-smoking history was obtained from each participant using questionnaires. RESULTS: Logistic regression analysis revealed that compared to controls, the frequencies of the A/A and C/A genotypes were significantly higher than those of the C/C genotype in cancerpatients (OR = 2.03, 95% confidence interval (CI) 1.03-3.98 and OR = 1.91, 95% CI 1.13-3.24, respectively). We also found that the frequency of the A/A genotype was significantly higher in cancer cases than in controls among non-smokers (OR = 7.7, 95% CI 1.38-42.88, compared to the C/C genotype). CONCLUSION: We found that the XPC intron11 C/A polymorphism was associated with an increased risk of prostate cancer. Among non-smokers, the A/A genotype was significantly more prevalent in prostate cancerpatients than in controls.
Entities:
Keywords:
Cancer risk; DNA repair gene; Prostate cancer; XPC-PAT; Xeroderma pigmentosum
Authors: Sei Chung Sak; Jennifer H Barrett; Alan B Paul; D Timothy Bishop; Anne E Kiltie Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-12 Impact factor: 4.254
Authors: Abdul Aziz Ahmad Aizat; Mohd Shahpudin Siti Nurfatimah; Mustapha Mohd Aminudin; Ravindran Ankathil Journal: World J Gastroenterol Date: 2013-06-21 Impact factor: 5.742
Authors: Somali Sanyal; Petra J De Verdier; Gunnar Steineck; Per Larsson; Erik Onelöv; Kari Hemminki; Rajiv Kumar Journal: Acta Oncol Date: 2007 Impact factor: 4.089
Authors: M Soledad Marín; M Felicitas López-Cima; Laura García-Castro; Teresa Pascual; Manuel G Marrón; Adonina Tardón Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-11 Impact factor: 4.254